Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923028 | 0.92 | GPR119 (0.52) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL2389411 | 0.88 | GPR119 (0.49) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL1842627 | 0.88 | GPR119 (0.55) | GPR119KCNH2GPR183 | |
| SCHEMBL2387551 | 0.88 | GPR119 (0.48) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL2387649 | 0.88 | GPR119 (0.48) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL2387557 | 0.88 | GPR119 (0.48) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL1922732 | 0.87 | GPR119 (0.63) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL2890800 | 0.86 | GPR119 (0.55) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL2890804 | 0.86 | GPR119 (0.55) | GPR119KCNH2GPR183HRH3 | |
| SCHEMBL2371746 | 0.86 | GPR119 (0.54) | GPR119KCNH2GPR183HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| EP-2328867-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885KCNH2 1299/4885GPR183 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.